{"links":{"feed":"https://www.erudio.com/reports/empowher-303-nct06435429/feed.json","html":"https://www.erudio.com/reports/empowher-303-nct06435429","json":"https://www.erudio.com/reports/empowher-303-nct06435429.json","markdown":"https://www.erudio.com/reports/empowher-303-nct06435429.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"empowher-303-nct06435429"}},"request":"https://www.erudio.com/contact?report=empowher-303-nct06435429"},"offer":{"cited_clinicians":3,"cited_commentary_sources":9,"verified_hcp_statements":49,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":8},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"empowher-303-nct06435429"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=empowher-303-nct06435429","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/empowher-303-nct06435429","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 49 verified statements · 28 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T22:14:31.072128Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":2,"title":"Proposed biological rationale for zanidatamab after T-DXd"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":6,"title":"Earlier zanidatamab evidence in advanced or pretreated breast cancer"},{"claim_count":9,"coverage":"discussed","id":"A3","source_count":4,"title":"Trial access, referral and reasons to consider participation"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":2,"title":"Sequencing, resistance and patient priorities across treatment"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":10,"cited_clinicians":3,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":2},"cited_physicians":3,"cited_sources":10,"claims_by_expression_type":{"experience":2,"interpretation":6,"opinion":15,"primary_context":2,"question":1,"restatement":19,"uncertainty":2,"unspecified":2},"claims_by_kind":{"protocol_statement":2,"source_observation":47},"clinician_statements":28,"evidence_units":23,"findings":7,"organisational_accounts":1,"people_cited":8,"people_identity_verified":8,"people_total":8,"screened_sources":18,"verified_claims":49},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":2,"views":3},"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":5,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Post-T-DXd treatment: why speakers look to EmpowHER-303 for answers","title_holders":{"cited_claim_ids":["claim-ac8fd7640f026a49394f","claim-d27bc407aeb5ae369e1d","claim-d8b5e698506c86ba2869","claim-9423f89a848798683591","claim-410ea2676c24103ab851"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"8 statements from 3 speakers in 4 sources, 2 of them podcasts or videos","holder_line":"3 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":0},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"media":2,"registry":1}},"title":"EmpowHER-303: what speakers say","evidence_line":"4 statements from 1 speaker in 3 sources, 2 of them podcasts or videos"},{"cited_clinicians":1,"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":4},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"media":2}},"title":"Zanidatamab: why a clinician links dual-site HER2 binding to possible benefit","title_holders":{"cited_claim_ids":["claim-918435cfe22995fbd390","claim-fd17acc58728384dfb9b","claim-e5bbc599fd3e72e4f776","claim-afb2e2ad7b567db75581"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"6 statements from 1 speaker in 2 sources, all podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":1},"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":1,"passages":4,"sources":3,"sources_by_kind":{"media":3}},"title":"EmpowHER-303 participation: why a clinician advises discussion and eligibility support","title_holders":{"cited_claim_ids":["claim-08b5b3070cbf9022b948"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"8 statements from 1 speaker in 3 sources, all podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"limitations":2,"links":{"context":1,"support":9},"ma_question":true,"named_voices":2,"passages":7,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Trials: a clinician advises more talks; a speaker welcomes expected Brazil entry","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-09b891f7ece21c361075"],"clause":"a speaker welcomes expected Brazil entry","holders":1},"cited_claim_ids":["claim-95836903bae9d4149cd5"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"9 statements from 2 speakers in 4 sources, 3 of them podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “a speaker welcomes expected Brazil entry”"},{"cited_clinicians":1,"id":"F6","population":"beyond","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":5},"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Earlier zanidatamab data: what speakers highlight in antitumor activity","title_holders":{"cited_claim_ids":["claim-c53ad17fcff1be09e706","claim-6b222d7bb5022eb674dc","claim-f52cc257cd02e90bc68c","claim-bb523883a244ff7b8993","claim-27d72d72ebb8cce3e1c6","claim-410ea2676c24103ab851"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"8 statements from 4 speakers in 5 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F7","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"HER2+ care: why a speaker weighs timing, resistance and lasting toxicity","title_holders":{"cited_claim_ids":["claim-3e8a39b7bab6a541274a","claim-c6f06d09626c277364fe","claim-34cef97e93c25396456a"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One speaker distinguishes a usual post-T-DXd option from an unsettled treatment question"},{"id":"section-2","level":2,"title":"One educational video describes a different control treatment"},{"id":"section-3","level":2,"title":"One speaker grounds possible benefit in dual-site HER2 targeting"},{"id":"section-4","level":2,"title":"One speaker directs patients to full eligibility information and their physician"},{"id":"section-5","level":2,"title":"One speaker encourages repeated trial conversations; one X account anticipates Brazilian availability"},{"id":"section-6","level":2,"title":"Beyond the trial population"},{"id":"section-7","level":3,"title":"X accounts see promise in earlier zanidatamab breast-cancer data"},{"id":"section-8","level":3,"title":"One discussion participant prioritizes timing, resistance and sustained treatment burden"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":4}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T22:14:31.072128Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T22:29:39Z","record_hash":"9aa9436f5f891898c8c48b630db14c6a6a7ad394070b41da4c478f70433cd055","release_hash":"4d062849615bbfa1373c947708df575e89b62641d712882733775298276fc6b4","report_id":"erudio-nct06435429","run_id":"725aea93-aabb-411c-bb90-fa25145bff09","schema_version":"5.0","slug":"empowher-303-nct06435429","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician described in the sources as presenting EmpowHER-303 sees treatment after T-DXd as unsettled, while identifying chemotherapy plus trastuzumab as a usual option. Their rationale for studying zanidatamab rests on earlier combination activity, which does not establish benefit in this setting. The sources reviewed for this edition contain no trial outcome data to judge added benefit or tolerability.","examples":[],"meta_description":"18 sources screened · 49 verified statements (28 from clinicians verified by NPI or staff page) from 10 sources · 7 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T22:29:39Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":18},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 32 sources about other trials or topics are not included.","The sources reviewed do not include an EmpowHER-303 outcome dataset. Earlier-phase activity, mechanistic expectations and participation counseling cannot establish comparative efficacy or safety in its post-T-DXd population.","No separate protocol or exact-trial results publication was identified for this edition. The complete eligibility criteria therefore cannot be reconciled from these discussions alone.","Searches emphasized explicit trial names and identifiers and may miss unnamed references or differently transcribed discussion. Absence of a criticism here does not establish that no such criticism exists.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker is described in the sources as presenting EmpowHER-303. Their views should not be counted as an independent external endorsement of the study.","A YouTube channel publisher describes an AI-generated avatar. Its narration has no proven individual speaker and includes a control-treatment description that conflicts with the registry.","Reposts are not additional independent clinical opinions. Neither source counts nor favorable comments establish consensus.","The sources reviewed do not establish a complete current regulatory picture across indications and countries; the video's approval wording remains a dated source statement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":6,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":9,"methods":1},"count":10,"evidence_window":{"end":"2026-10-16","start":"2024-12-13"},"retrieval_snapshot":"2026-11-19T21:14:20.686108Z","timeline":[{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W14"},{"count":4,"week":"2025-W20"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W42"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06435429:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06435429:context","quote_policy":"short_quote_link_out"},{"id":"openfda:ae5d9425-fae5-4541-a158-150998343348:20260824","quote_policy":"short_quote_link_out"},{"id":"openfda:27dd5e6b-72cd-458d-a015-cf4dab5800da:20260923","quote_policy":"short_quote_link_out"},{"id":"openfda:9bfd8ac7-57e2-4c9d-add8-26502cfb54a8:20261110","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-j3xcgqerae6yhbp7l7yycbyx-3lcfhdqg2jc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lqyrvj7xji2v","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1863897131070726651:125f54e0-c3bb-4c33-94c5-05097143571b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867664539170275420:b619c27c-cb03-465f-9285-98bd8744618f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923276419028685279:e759a319-2942-430b-9f8d-6f76d49e50e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923276822789120496:26a26ab2-0413-4bf5-8c36-9ebba8e205d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923276847145533442:decc066e-21ba-4cf3-b28f-9ec1bc96d851","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923277364345143525:837c9c5a-9436-4af3-9c41-9a861d709ef6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923278081277456740:bc0da5a6-ffec-472f-b213-352af1496e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923283289005019274:421ae58d-1843-4cdd-a203-0b70d6ed3503","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923314928641081489:6db1ade1-c4bc-49c6-8f67-96674f7cd0cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925979956862984202:e9525c98-2410-478e-8992-7eb4e94cfca6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925980227756331199:40aac52d-7311-44a4-a459-174391ccaf57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938665029802565678:c7ce756d-caa1-4328-b24a-0216a140c89b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065084036486201493:a7d18f3f-220b-41a1-8503-0212f4905d7a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:V68JwicKdLU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_-aULXYOLhk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pNzip7U4CJM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-10-16","start":"2024-12-03"},"retrieval_snapshot":"2026-11-19T21:14:20.686108Z","timeline":[{"count":2,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W14"},{"count":7,"week":"2025-W20"},{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":2,"regulatory":0,"x_thread":11,"x_video":0,"youtube":36}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Ziihera"],"label":"zanidatamab","slug":"zanidatamab"},{"brand_names":["Herceptin"],"label":"trastuzumab","slug":"trastuzumab"},{"brand_names":["Halaven"],"label":"eribulin","slug":"eribulin"},{"brand_names":["Navelbine"],"label":"vinorelbine","slug":"vinorelbine"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"}],"indications":[{"reason":"Unmapped registry condition: Metastatic HER2-positive Breast Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EmpowHER-303","aliases":["EmpowHER-303","JZP598-303","A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment"],"brief_title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic HER2-positive Breast Cancer"],"display_condition":"metastatic HER2-positive breast cancer","display_interventions":[["zanidatamab"]],"enrollment":{"count":550,"type":"ESTIMATED"},"interventions":[{"name":"Zanidatamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Trastuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Eribulin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Vinorelbine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Capecitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06435429","official_title":"A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-04-28","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by BICR according to RECIST v1.1) or death from any cause, whichever occurs first.","measure":"Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Until disease progression or death, up to approximately 44 months"}],"registered_date":{"date":"2024-05-30","type":"ACTUAL"},"registry_last_updated":"2026-02-10","registry_url":"https://clinicaltrials.gov/study/NCT06435429","short_name":"EmpowHER-303","short_name_basis":"canonical_name","sponsor":"Jazz Pharmaceuticals","start_date":{"date":"2024-08-13","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"JZP598-303","type":"sponsor_study_id"},{"domain":"EU CTR","id":"2023-508960-31-00","type":"other"}],"study_type":"INTERVENTIONAL"}}}